title: [Anti-cD20scFv/CD80/CD28/zeta specific T lymphocytes eradicate primary chronic lymphocytic leukemia cells in vitro].
abstract: OBJECTIVE
  To construct anti-CD20scFv/CD80/CD28/zeta recombinant gene modified T cells, test its effectiveness of eradicating CD20 positive primary chronic lymphocytic leukemia (CLL) cells and provide a promising tool for tumor adoptive immunotherapy.
  
  
  METHODS
  The recombinant vectors were transduced into PA 317 cells and high titer retroviruses were obtained to infect human peripheral blood T lymphocytes. Resistant T cells were obtained by G418 selection for one week. Then transduced T lymphocytes and primary CLL cells were co-cultured. The status of primary chronic lymphocytic leukemia cells were observed by microscope. The level of IL-2 and IFN-gamma in the culture medium were measured.
  
  
  RESULTS
  Primary T cells expressing anti-CD20scFv/IgGFc/CD80/CD28/zeta could be constructed successfully. These T cells were able to lyse CD20+ targets and secrete high levels of IL-2 (1301.00 pg/ml) and IFN-gamma (602.18 pg/ml) in vitro.
  
  
  CONCLUSIONS
  (1) Recombinant gene modified T cells can be constructed successfully. (2) Recombinant gene modified T cells can specially kill CD20 positive primary CLL cells in vitro.
authors.affiliation: Department of Hematology, First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China.
authors.forename: Hong-Lan
authors.initials: HL
authors.lastname: Qian
authors.forename: Kang
authors.initials: K
authors.lastname: Yu
authors.forename: Zhi-Jian
authors.initials: ZJ
authors.lastname: Shen
authors.forename: Bin
authors.initials: B
authors.lastname: Liang
authors.forename: Sheng
authors.initials: S
authors.lastname: Luo
authors.forename: Chong-Yun
authors.initials: CY
authors.lastname: Xing
authors.forename: Yong-Xian
authors.initials: YX
authors.lastname: Hu
mesh_terms: D018951:Antigens, CD20 / Q000235:genetics*; D018122:B7-1 Antigen / Q000235:genetics; D018106:CD28 Antigens / Q000235:genetics; D005822:Genetic Vectors; D006801:Humans; D016219:Immunotherapy, Adoptive; D007371:Interferon-gamma / Q000378:metabolism; D007376:Interleukin-2 / Q000378:metabolism; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000473:pathology; D012190:Retroviridae / Q000235:genetics; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D018951:Antigens, CD20; D018122:B7-1 Antigen; D018106:CD28 Antigens; C508594:IL2 protein, human; D007376:Interleukin-2; D007371:Interferon-gamma